Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. Cancers Wagner, M. J., Hennessy, C., Beeghly, A., French, B., Shah, D. P., Croessmann, S., Vilar-Compte, D., Ruiz-Garcia, E., Ingham, M., Schwartz, G. K., Painter, C. A., Chugh, R., Fecher, L., Park, C., Zamulko, O., Trent, J. C., Subbiah, V., Khaki, A. R., Tachiki, L., Nakasone, E. S., Loggers, E. T., Labaki, C., Saliby, R. M., McKay, R. R., Ajmera, A., Griffiths, E. A., Puzanov, I., Tap, W. D., Hwang, C., Tejwani, S., Jhawar, S. R., Hayes-Lattin, B., Wulff-Burchfield, E., Kasi, A., Reuben, D. Y., Nagaraj, G., Joshi, M., Polimera, H., Kulkarni, A. A., Esfahani, K., Kwon, D. H., Paoluzzi, L., Bilen, M. A., Durbin, E. B., Grivas, P., Warner, J. L., Davis, E. J., COVID-19 and Cancer Consortium 2022; 14 (17)

Abstract

BACKGROUND: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.METHODS: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.RESULTS: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity.CONCLUSIONS: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.

View details for DOI 10.3390/cancers14174334

View details for PubMedID 36077869